A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 230
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LABAs
Long Form : long-acting beta2-agonists
No. Year Title Co-occurring Abbreviation
2022 A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort. HR, ICSs, LAMAs, LTRAs
2022 Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. COPD, IRRs, PS
2022 Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China. FSC, LAMAs, LYs, QALYs, UMEC/VIL
2022 Dual bronchodilation for the treatment of COPD: From bench to bedside. COPD, FDCs, LAMAs, RCTs, SGRQ, SUCRA, TDI
2022 Optimizing asthma management: Role of long-acting muscarinic antagonists. ICS, LAMAs
2022 The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. COPD, ICERs, LAMAs, QALYs, TIO, WTP
2022 The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. FDC, ICSs, LAMAs, RCTs
2021 Can we minimize carbon footprint by using "greener" inhalers and improve clinical outcome at the same time in asthma therapy? DPI, LAMAs, pMDIs, SABAs
2021 Carbon footprint of inhalers in COPD therapy in 2018 and 2019 in Poland in response to the Kigali amendment. DPI, LAMAs, pMDIs, SAMAs
10  2021 Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study. FDCs, FF/BDP, FF/BUD, HR, ICS, IND/GLY, IRR, LABA/ICS, LABA/LAMA, LAMAs, SAL/FP, VI/UMEC
11  2021 Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane. ACh, CFTR, COPD, IND, LPS
12  2021 Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. CI
13  2021 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. FEV1, FF, FP, FVC, ICSs, LAMAs, LSM
14  2021 Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. CAT, COPD, FEV1, ICS, LAMAs, MACE
15  2021 Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States. COPD, GOLD, LAMAs, TT
16  2021 Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. CCP-UK, HR, ISARIC, OR, SABAs
17  2021 State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma. beta2-agonists, GINA, NIH/NLM, SABAs
18  2021 The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. COPD, FP, ICS
19  2021 Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients. ICS, SCS
20  2021 Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. ICS, LAMAs, RCTs, SMD
21  2021 Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma. ICS, LAMAs, OCS
22  2020 A comparison of tiotropium, long-acting beta2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma. AEs, ICS, LAMAs, LTRAs, RCTs
23  2020 A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. COPD, ECG
24  2020 Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD. BP, bpm, COPD, HR, LAMAs
25  2020 Assessment of Patient Experiences with Respimat in Everyday Clinical Practice. COPD, GOLD, LAMAs, SMI
26  2020 Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study). ACT, CAT, COPD, FDC, ICS
27  2020 Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis. CBM, CENTRAL, CNKI, ICS
28  2020 Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. ICS, LAMA, LTRAs
29  2020 Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. LAMAs, NMA, RCTs
30  2020 Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. CI, COPD, FEV1, ICS, LAMAs, RCT, SGRQ, TDI
31  2020 Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane? COPD, GOLD, ICS, LAMA
32  2020 Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years. ED, GERA, ICS, OCS
33  2020 Tiotropium in asthma - perspectives for the primary care physician. GINA, ICS, RCTs
34  2020 Treatment of COPD and COPD-heart failure comorbidity in primary care in different stages of the disease. COPD, HF
35  2019 Clinical predictors of asthmatics in identifying subgroup requiring long-term tiotropium add-on therapy: a real-world study. ACT, BMI, COPD, GINA, ICS, LAMA
36  2019 Comparative Effectiveness and Safety of LABA-LAMA vsLABA-ICS Treatment of COPD in Real-World Clinical Practice. HR, LABA-ICS, LAMAs
37  2019 Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. COPD, CrI, ICSs, LAMAs, NMA, OR, PROSPERO, RCTs, SR
38  2019 Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. CAEs, CF, CIs, COPD, IHD, ILABs, LAMAs, ORs
39  2019 Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37. AJs, COPD, CSE, GCSs, JAM-A, TEER, TJs, ZO-1
40  2019 Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event. ARF, COPD, DME, ED, HRU, ICD-9-CM, ICSs
41  2019 Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. COPD, FDA, LAMAs
42  2019 Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. COPD, FDCs, LAMAs
43  2019 LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD. COPD, HASMCs, ICS, p38 MAPKs
44  2019 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ICSs
45  2019 Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. HCRU, ICSs
46  2019 Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer in patients with persistent asthma in India. ICS, PEFR
47  2019 Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. AEs, COPD, ILABs, LAMAs, OCAEs
48  2019 Single Inhaler LABA/LAMA for COPD. COPD, LAMAs
49  2019 The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. CI, COPD, ICSs, LAMAs
50  2019 [The stepwise approach of COPD therapy]. COPD, ICS, LAMAs
51  2018 Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. COPD, CVD, LAMAs
52  2018 Association of Inhaled Corticosteroids and Long-Acting beta-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. RDs, RRs, SMART
53  2018 Combined Analysis of Asthma Safety Trials of Long-Acting beta2-Agonists. CI, FDA
54  2018 Effect of long-acting beta2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. BP, COPD
55  2018 Inaccurate diagnosis of COPD: the Welsh National COPD Audit. COPD, ICS, LAMAs, MRC, QOF
56  2018 Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? ICSs
57  2018 Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. LAMAs
58  2018 Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. CI, FDA, ICSs, OR, SAEs
59  2018 LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. COPD, FDCs, HRQoL, HS, LAMAs, PROs, RCTs
60  2018 Long-Acting beta2-Agonists in Asthma: Enantioselective Safety Studies are Needed. BHR, ICSs, SABA
61  2018 Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. ICS
62  2018 New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. FDC, LAMAs, MDI
63  2018 Pattern and Adherence to Maintenance Medication Use in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease: 2008-2013. CI, COPD, ICSs, LAMAs, OR, PDC
64  2018 Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. COPD, ICS
65  2018 The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study. COPD, DSCs
66  2018 Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease. COPD, LABDs, SABAs, SAMAs
67  2018 Triple therapy versus single and dual long-acting bronchodilator therapy inCOPD: a systematic review and meta-analysis. ICS, LAMAs, NNT
68  2017 A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma. ICS
69  2017 Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. FEV1, OD
70  2017 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. AMI, HR
71  2017 Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. LAMAs, QALYs, TIO
72  2017 Effects of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice. BALF, KC, MIP-1beta
73  2017 Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study. DLH, LAMAs
74  2017 Formoterol and fluticasone propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial epithelial cells exposed to cigarette smoke. CSE, FO, FP
75  2017 GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond. COPD, FDC, LAMAs, MDI
76  2017 Long-Acting beta2-Agonists and Risk of Hypertensive Disorders of Pregnancy: A Cohort Study. HDP
77  2017 Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease. COPD, LAMAs
78  2017 Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. COPD, FDCs, IND/GLY, LAMAs
79  2017 Safety of inhaled long-acting anti-muscarinic agents in COPD. ICS, LAMAs
80  2017 Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy. LAMAs
81  2017 Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. ICSs
82  2017 The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. FDCs, LAMAs, SAEs
83  2017 Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD, ICS, LAMAs
84  2016 Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies. CV, FFS, ICSs, LTRAs, OR
85  2016 Assessing the viability of long-acting beta2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. ICSs, PD, PK
86  2016 Changing patterns of asthma medication use related to US Food and Drug Administration long-acting beta2-agonist regulation from 2005-2011. FDA, ICSs
87  2016 Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. COPD, LAMAs
88  2016 Efficacy and safety of conventional long acting beta2- agonists: systematic review and meta-analysis. CI, COPD, RCTs, RR
89  2016 Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. COPD, FDCs, LAMAs, PROs, UMEC/VI
90  2016 Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA. FEV1, FRI, ICSs, LAMAs
91  2016 Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. ADRB2, COPD, FEV1, FVC, GWAS, HLA, LAMAs, SNPs
92  2016 Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. B2AR, F/S, ICS/LABA
93  2016 Level of Asthma Controller Therapy Before Admission to the Hospital. ICS
94  2016 New combinations in the treatment of COPD: rationale for aclidinium-formoterol. COPD, LAMAs
95  2016 Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. LAMAs
96  2016 Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. CI
97  2016 Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. AUC, COPD, ICS, NPV, PPV
98  2016 Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. CI
99  2016 The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. ICS
100  2016 Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. FEV1, ICS